Showing 15 posts of 18 posts found.


New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …


MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations

May 29, 2020
Medical Communications, Research and Development Lenvima, keytruda, pharma

MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …


Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer

February 17, 2020
Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma

New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …

US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer

September 18, 2019
Research and Development, Sales and Marketing Australian Therapeutic Goods Administration, Cancer, FDA, Health Canada, Lenvima, keytruda, pharma

The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, …

NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer

December 19, 2018
Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma

UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …


Eisai’s Lenvima wins over NICE in liver cancer in just three months

November 9, 2018
Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …


Eisai and MSD team up to combine Lenvima and Keytruda in cancer

March 8, 2018
Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …


EU approval for Eisai kidney cancer treatment

September 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus

The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …


Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …


Eisai partners with Novartis in renal cell carcinoma collaboration

June 3, 2016
Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate

Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …


Eisai slams new Cancer Drugs Fund for delaying patient access

February 26, 2016
Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …

Eisai logo

FDA grants Eisai’s Lenvima priority review for kidney cancer

January 19, 2016
Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma

The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …


Eisai submits new cancer combo to EMA for approval

January 12, 2016
Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …

EMA image

EMA committee recommends five drugs for approval

March 30, 2015
Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly

Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …

Latest content